A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

Trial Details

NCT ID
NCT07192614
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • AZD6621
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Commack, New York, United States|40.84288,-73.29289

Key Eligibility Criteria

  • Capable of giving signed informed consent and complying to the study protocol.
  • Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form.
  • ≥ 18 years of age at the time of signing the informed consent form.
  • Participants with:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →